Mergers & Acquisitions ·
Rigel Pharmaceuticals, Inc. completed the acquisition of exclusive, global rights to develop, manufacture, and…
RIGLRigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc. completed the acquisition of exclusive, global rights to develop, manufacture, and commercialize VEPPANU™ (vepdegestrant) and related products worldwide through a License Agreement with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc., and Pfizer Inc. The transaction, which involved a one-time upfront payment of $70.0 million, became effective following the satisfaction of all closing conditions and the Hart-Scott-Rodino Antitrust Improvements Act waiting period termination. Rigel Pharmaceuticals, Inc. is a biopharmaceutical company focused on small molecule drugs for various medical conditions.